DOCSLIB.ORG

IBAL01 3047 RA13 EN V4.Indd

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
IBAL01 3047 RA13 EN V4.Indd ANNUAL REVIEWANNUAL 2013 IBA 2013 // ANNUAL REVIEW ANNUAL // IBA KEY FIGURES INTRODUCTION 2013 MARGIN TRENDS IBA is a high-technology medical OUR MISSION: company which concentrates SAVING LIVES 10% its activities on proton therapy, radiopharmacy, particle accelerators 8% for the industry and dosimetry. IBA is the worldwide leader on the 6% proton therapy market. At IBA we dare to develop innovative solutions 4% Quoted on the pan-European stock pushing back the limits of technology. We share ideas exchange Euronext. 2% and know-how with our customers and our partners 1 000 employees worldwide. to bring new solutions for the diagnosis and treatment IBA operates in two segments: 0% of cancer. We care about the well-being of patients, 2008 2009 2010 2011 2012 2013 “Proton therapy and Particle our employees and our shareholders as it is together 1 accelerators” and “Dosimetry”. that we complete our mission to: Protect, Enhance 2013 and Save Lives. 2013 SALES TRENDS BY ACTIVITY* // ANNUAL REVIEW ANNUAL // // ANNUAL REVIEW ANNUAL // IBA IBA 2009 2010 2011 2012 2013 CAGR (1) (EUR 000) (EUR 000) (EUR 000) (EUR 000) (EUR 000) (%) TURNOVER 155 574 169 988 203 165 221 106 212 512 8.1% Proton therapy 70 689 82 884 121 157 133 213 121 202 14.4% Other Accelerators 45 070 39 086 38 896 38 991 45 387 0.2% CONTENTS Dosimetry 39 815 48 018 43 112 48 902 45 923 3.6% IBA at a glance 2 (1) Compound annual growth rate. Highlights 2013 4 Global strategy 6 Human resources 20 Board of Directors & Management Team 22 A global presence 24 Economic review 26 SALES TRENDS BY GEOGRAPHICAL SECTOR (%)* Key fi gures 27 Operating results 27 2009 2010 2011 2012 2013 Stock market and shareholders 28 USA 52 33 34 38 35 *The fi gures do not include any ROW 48 67 66 62 65 pharmaceutical activity. OUR SOLUTIONS TODAY, IBA FOCUSES Today, more than half of proton prescribed dose to a precisely therapy clinical facilities worldwide defi ned area in the patient’s body ON THREE are IBA systems. At the end of is absolutely crucial. Treatment MAIN ACTIVITIES 2013, this includes 16 proton success and safety depend on it. therapy centers in operation and 10 additional centers under PARTICLE PROTON THERAPY development. ACCELERATORS The IBA product offer ranges 56% 2013 ACTIVITY TURNOVER 21% 2013 ACTIVITY TURNOVER from complete solutions 121 202 (EUR 000) with Proteus ®PLUS with 45 387 (EUR 000) several treatment rooms to To date, IBA has installed more Proton therapy is considered to Proteus ®ONE (1) , a single-room than 400 accelerators worldwide. be the most advanced treatment solution. With Proteus ®ONE , The majority of them are used for in the fi ght against cancer, thanks proton therapy is more accessible the production of radioisotopes for to the precision with which it is than ever. possible to target the tumor and the detection of cancer. The IBA its reduced side effects. Protons Radiopharma Solutions team helps deposit the majority of their energy DOSIMETRY nuclear medicine departments to design, install and maximize within a precisely controlled 23% 2013 ACTIVITY TURNOVER zone, directly in the center of the the functional effi ciency of a 45 923 (EUR 000) tumor without damaging healthy radiopharmacy for the production (1) Proteus®ONE is of radiopharmaceuticals, the brand name of surrounding tissues. IBA offers a full range of mainly PET (Positron Emission a new confi guration 2 IBA Proton therapy is particularly monitoring equipment and of the Proteus® 3 Tomography). software enabling hospitals to 235, including some appropriate to treat eye and brain new developments perform the necessary checks and In addition to its medical activity, 2013 2013 cancers, tumors close to the brain subject to review 2013 stem and spinal cord, as well as calibration procedures of radiation IBA leverages its scientifi c by competent therapy and radiology. Precision expertise in radiation to develop its authorities (FDA, prostate, liver, breast and pediatric European Notifi ed AT A GLANCE is everything in the delivery of industrial sterilization and ionization cancers. Bodies, et al.) radiation. Delivering exactly the activities. before marketing. // ANNUAL REVIEW ANNUAL // // ANNUAL REVIEW ANNUAL // REVIEW ANNUAL // IBA IBA IBA IBA is the worldwide technology leader in advanced cancer radiation therapy and diagnostic technologies. The Company’s special expertise lies in the development of innovative proton therapy technologies, supplying the oncological world with equipment of unequalled precision. Proteus ®PLUS HIGHLIGHTS 2013 2013 a record sales year for HIGHLIGHTS RadioPharma 2013 Solutions. IBA market share 66 % of proton therapy rooms in operations. à November 27th, 2013 à During 2013, IBA equipped à November 4th, 2013 • An extended version of Proton IBA receives FDA clearance for several proton therapy centers IBA signs a contract with the successful MatriXX to Operating Therapy its new Imaging Suite, a solid with its unique PBS technology Zevacor Molecular to address patient treatment highlights foundation for the development which enables millimeter install the first commercial verification of new treatment st th à January 21 , 2013 of future Image-Guided Proton precision in cancer treatment. 70 MeV Cyclotron dedicated technologies (high dose rate). à June 4 , 2013 4 IBA signs contract with Apollo Therapy (IGPT) solutions. to the production of IBA makes further good 5 à Throughout 2013 IBA continued • A new release of Compass Hospitals to install the first radiopharmaceuticals in progress towards reaching à Major milestones were to demonstrate its capacity to (3.0) that enables even faster 2013 proton therapy center in India. the United States, allowing a final settlement with 2013 achieved in 2013 in the accelerate the pace at which and more accurate patient With this contract, IBA will be it to provide the year-round Westdeutsches Protonen- development of IBA’s compact newly constructed proton treatment verification in 3D at the forefront of delivering the production of isotopes used in therapiezentrum Essen GmbH proton therapy system, therapy centers are ready to anatomy. latest innovative cancer therapy the diagnosis of cardiovascular (WPE). The final contract was Proteus®ONE: treat patients. The installation to the Asia region. diseases and other critical • The replacement software signed in March 2014. of proton therapy rooms were // ANNUAL REVIEW ANNUAL // // ANNUAL REVIEW ANNUAL // à June 2nd, 2013 • IBA submitted all necessary illnesses. for 2D patient verification à November 13th, 2013 IBA completed in Trento (Italy), IBA documentation on IBA’s has new functionalities that IBA gathers more than 60 Seattle (USA) and Knoxville à In 2013 IBA signed major The Company announces compact proton therapy increase efficiency through radiation therapy leaders in its (USA) in 2013. contracts for the supply of receipt of payment from the gantry to the U.S. Food and an improved workflow and factory in Belgium to discover Rhodotron® and Dynamitron® ATreP (Agenzia Provinciale ® Drug Administration (FDA) graphical user interface the firstProteus ONE proton accelerators in Asia and Brazil. Per la Protonterapia) center in therapy system. for marketing authorization. management. Trento, Italy, in repayment of the loan facility signed in 2009. à July 1st, 2013 • The compact gantry beam Particle • A new product extension to IBA signs contract to install line was shipped to Willis- the VISICOIL product line, à November 18th, 2013 Proteus®ONE in Taiwan. This Knighton Cancer Center Accelerators Dosimetry designed for safer and easier IBA completes the sale of its (WKCC) in Shreveport, implantation in interventional contract demonstrates IBA’s à 2013 was a record year of sales à IBA Dosimetry introduced Cisbio Bioassays business unit Louisiana. radiology. This new product continued success in Asia. for IBA RadioPharma Solutions several product improvements to an Argos Soditic fund. division. IBA won important supports radiation oncologists à October 9th, 2013 • IBA also accelerated at major tradeshows (American à December 11th, 2013 contracts in all regions, which in highly precise patient setup IBA is selected by the Henryk and extracted a proton Association of Physicists IBA reaches agreement with strengthened IBA’s position as and dose delivery during Niewodniczanski Institute of beam from its compact in Medicine (AAPM) and SK Capital Partners to settle all the leader in medium- and high- radiation therapy. Nuclear Physics of the Polish Synchrocyclotron, to levels American Society for Radiation outstanding disputes between energy cyclotrons. Academy of Sciences (IFJ) to suitable for being used Oncology (ASTRO) annual the two parties under the Share supply the new extension of the by Pencil Beam Scanning meetings), that were well Purchase Agreement, which IFJ Proton Therapy Center, in (PBS) technologies. received by the market, was closed in early April 2012. Krakow, Poland. including: GLOBAL STRATEGY Left Pierre Mottet, Chairman GLOBAL Right Olivier Legrain, STRATEGY CEO 2014 the harvest year. 6 à 2013 was the year the company à 2014 should be the year of harvest. 7 repositioned to focus on its core We look forward to starting treatment 2013 2013 businesses: proton therapy, dosimetry of the first patient on our new compact 2013 and particle accelerators. This proton therapy solution Proteus®ONE, repositioning allows IBA to position and seeing a growing number of // ANNUAL // ANNUAL REVIEW // ANNUAL REVIEW ANNUAL // itself for the future and consolidate hospitals worldwide adopting proton REVIEW ANNUAL // IBA IBA its leadership on the growing proton therapy. IBA will reap the benefits of IBA therapy market. IBA has also assured an increasing number of long-term its leadership in the dosimetry field service contracts as well as a strong and ended a record year for sales order backlog. The Company should of accelerators for radiopharmacies reach 10% of operating profit at the end and industrial applications, mainly of 2014. to emerging countries. Operating margins rose strongly, mainly from productivity and efficiency programs put in place, and from higher service- based revenues.
Load more

Recommended publications
  • Proton Stereotactic Body Radiation Therapy for Liver Metastases— Results of 5-Year Experience for 81 Hepatic Lesions
    1760 Original Article Proton stereotactic body radiation therapy for liver metastases— results of 5-year experience for 81 hepatic lesions Alex R. Coffman1, Daniel C. Sufficool2, Joseph I. Kang1, Chung-Tsen Hsueh3, Sasha Swenson4, Patrick Q. McGee4, Gayathri Nagaraj3, Baldev Patyal1, Mark E. Reeves5, Jerry D. Slater1, Gary Y. Yang1 1Department of Radiation Oncology, Loma Linda University Medical Center, Loma Linda, CA, USA; 2Department of Radiation Oncology, Kettering Health Network, Kettering, OH, USA; 3Department of Medical Oncology, Loma Linda University Medical Center, Loma Linda, CA, USA; 4Loma Linda University School of Medicine, Loma Linda, CA, USA; 5Department of Surgical Oncology, Loma Linda University Medical Center, Loma Linda, CA, USA Contributions: (I) Conception and design: GY Yang; (II) Administrative support: B Patyal, JD Slater, GY Yang; (III) Provision of study materials or patients: CT Hsueh, G Nagaraj, ME Reeves; (IV) Collection and assembly of data: AR Coffman, GY Yang; (V) Data analysis and interpretation: AR Coffman, GY Yang; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors. Correspondence to: Alex R. Coffman, MD. Department of Radiation Oncology, Loma Linda University Medical Center, 11234 Anderson Street, Suite B121, Loma Linda, CA 92354, USA. Email: [email protected]. Background: To report on our institutional experience using Proton stereotactic body radiation therapy (SBRT) for patients with liver metastases. Methods: All patients with liver metastases treated with Proton SBRT between September 2012 and December 2017 were retrospectively analyzed. Local control (LC) and overall survival (OS) were estimated using the Kaplan-Meier method calculated from the time of completion of Proton SBRT. LC was defined according to Response Evaluation Criteria in Solid Tumors (RECIST) guidelines (version 1.1).
    [Show full text]
  • An Analysis of Vertebral Body Growth After Proton Beam Therapy for Pediatric Cancer
    cancers Article An Analysis of Vertebral Body Growth after Proton Beam Therapy for Pediatric Cancer Keiichiro Baba 1, Masashi Mizumoto 1,* , Yoshiko Oshiro 1,2, Shosei Shimizu 1 , Masatoshi Nakamura 1, Yuichi Hiroshima 1 , Takashi Iizumi 1, Takashi Saito 1, Haruko Numajiri 1, Kei Nakai 1 , Hitoshi Ishikawa 1,3, Toshiyuki Okumura 1, Kazushi Maruo 4 and Hideyuki Sakurai 1 1 Proton Medical Research Center, Department of Radiation Oncology, University of Tsukuba Hospital, Tsukuba, Ibaraki 305-8576, Japan; [email protected] (K.B.); [email protected] (Y.O.); [email protected] (S.S.); [email protected] (M.N.); [email protected] (Y.H.); [email protected] (T.I.); [email protected] (T.S.); [email protected] (H.N.); [email protected] (K.N.); [email protected] (H.I.); [email protected] (T.O.); [email protected] (H.S.) 2 Department of Radiation Oncology, Tsukuba Medical Center Hospital, Tsukuba, Ibaraki 305-8558, Japan 3 National Institutes for Quantum and Radiological Science and Technology, QST Hospital, Chiba 263-8555, Japan 4 Department of Clinical Trial and Clinical Epidemiology, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki 305-8575, Japan; [email protected] * Correspondence: [email protected]; Tel.: +81-29-853-7100; Fax: +81-29-853-7102 Simple Summary: Radiotherapy has a key role in treatment of pediatric cancer and has greatly improved survival in recent years. However, vertebrae are often included in the irradiated area, and this may affect growth after treatment.
    [Show full text]
  • Particle Accelerators and Detectors for Medical Diagnostics and Therapy Arxiv:1601.06820V1 [Physics.Med-Ph] 25 Jan 2016
    Particle Accelerators and Detectors for medical Diagnostics and Therapy Habilitationsschrift zur Erlangung der Venia docendi an der Philosophisch-naturwissenschaftlichen Fakult¨at der Universit¨atBern arXiv:1601.06820v1 [physics.med-ph] 25 Jan 2016 vorgelegt von Dr. Saverio Braccini Laboratorium f¨urHochenenergiephysik L'aspetto pi`uentusiasmante della scienza `eche essa incoraggia l'uomo a insistere nei suoi sogni. Guglielmo Marconi Preface This Habilitation is based on selected publications, which represent my major sci- entific contributions as an experimental physicist to the field of particle accelerators and detectors applied to medical diagnostics and therapy. They are reprinted in Part II of this work to be considered for the Habilitation and they cover original achievements and relevant aspects for the present and future of medical applications of particle physics. The text reported in Part I is aimed at putting my scientific work into its con- text and perspective, to comment on recent developments and, in particular, on my contributions to the advances in accelerators and detectors for cancer hadrontherapy and for the production of radioisotopes. Dr. Saverio Braccini Bern, 25.4.2013 i ii Contents Introduction 1 I 5 1 Particle Accelerators and Detectors applied to Medicine 7 2 Particle Accelerators for medical Diagnostics and Therapy 23 2.1 Linacs and Cyclinacs for Hadrontherapy . 23 2.2 The new Bern Cyclotron Laboratory and its Research Beam Line . 39 3 Particle Detectors for medical Applications of Ion Beams 49 3.1 Segmented Ionization Chambers for Beam Monitoring in Hadrontherapy 49 3.2 Proton Radiography with nuclear Emulsion Films . 62 3.3 A Beam Monitor Detector based on doped Silica Fibres .
    [Show full text]
  • Proton Therapy ACKNOWLEDGEMENTS
    AMERICAN BRAIN TUMOR ASSOCIATION Proton Therapy ACKNOWLEDGEMENTS ABOUT THE AMERICAN BRAIN TUMOR ASSOCIATION Founded in 1973, the American Brain Tumor Association (ABTA) was the first national nonprofit organization dedicated solely to brain tumor research. For over 40 years, the Chicago-based ABTA has been providing comprehensive resources that support the complex needs of brain tumor patients and caregivers, as well as the critical funding of research in the pursuit of breakthroughs in brain tumor diagnosis, treatment and care. To learn more about the ABTA, visit www.abta.org. We gratefully acknowledge Anita Mahajan, Director of International Development, MD Anderson Proton Therapy Center, director, Pediatric Radiation Oncology, co-section head of Pediatric and CNS Radiation Oncology, The University of Texas MD Anderson Cancer Center; Kevin S. Oh, MD, Department of Radiation Oncology, Massachusetts General Hospital; and Sridhar Nimmagadda, PhD, assistant professor of Radiology, Medicine and Oncology, Johns Hopkins University, for their review of this edition of this publication. This publication is not intended as a substitute for professional medical advice and does not provide advice on treatments or conditions for individual patients. All health and treatment decisions must be made in consultation with your physician(s), utilizing your specific medical information. Inclusion in this publication is not a recommendation of any product, treatment, physician or hospital. COPYRIGHT © 2015 ABTA REPRODUCTION WITHOUT PRIOR WRITTEN PERMISSION IS PROHIBITED AMERICAN BRAIN TUMOR ASSOCIATION Proton Therapy INTRODUCTION Brain tumors are highly variable in their treatment and prognosis. Many are benign and treated conservatively, while others are malignant and require aggressive combinations of surgery, radiation and chemotherapy.
    [Show full text]
  • PIONEERING THERAPY for LIFE Table of Contents
    PIONEERING THERAPY FOR LIFE Table of contents Key figures 20151 IBA at a glance 2 IBA is 30 years old 4 Proton therapy 6 Dosimetry 20 RadioPharma Solutions 24 Industrial 26 Human resources 28 Corporate social responsibility 30 Governance 36 Economical review 39 IFRS consolidated financial statements for the year ended December 31, 2015 73 IBA SA Annual financial statements148 General information 152 Stock market and shareholders 157 Key figures 2015 REBIT (3) / SALES & SERVICES TRENDS 12% 12 IBA is a high-technology medical 10.9% company which concentrates 10% 10 its activities on proton therapy, radiopharmacy, particle accelerators 8 8% for industry, and dosimetry. 6% IBA is the worldwide leader in 6 the proton therapy market. 4 4% Listed on the NYSE Euronext Brussels. 2 2% 1 200 employees worldwide. 0% IBA operates in two areas: “Proton 0 Therapy and Other Accelerators ” and 2010 2011 2012 2013 2014 2015 “Dosimetry”. Key figures 2015 + 22.6% 332 2015 revenue increase EUR million Backlog in Proton Therapy & Other Accelerators OPERATING RESULTS 2014 2015 Change CAGR (1) (EUR 000) (EUR 000) (EUR 000) (%) 2014/2015 Sales and services 220 577 270 357 49 780 22.60% Gross margin 96 096 113 655 18.30% REBITDA (2) 28 321 33 710 5 389 19.00% REBITDA/Sales and services 12.80% 12.50% REBIT (3) 22 932 29 553 6 621 28.90% REBIT/Sales and services 10.40% 10.90% Net profit 24 294 61 189 36 895 151.90% (1) CAGR: compound annual growth rate (2) REBITDA: recurring earnings before interest, taxes, depreciation, and amortization.
    [Show full text]
  • Clinical Policy: Proton and Neutron Beam Therapies Reference Number: CP.MP.70 Coding Implications Last Review Date: 11/20 Revision Log
    Clinical Policy: Proton and Neutron Beam Therapies Reference Number: CP.MP.70 Coding Implications Last Review Date: 11/20 Revision Log See Important Reminder at the end of this policy for important regulatory and legal information. Description Proton beam therapy (PBT) is a form of external beam radiation therapy (EBRT) that utilizes protons (positively charged subatomic particles) to precisely target a specific tissue mass. Proton beams can penetrate deep into tissues to reach tumors, while delivering less radiation to surrounding tissues. This may make PBT more effective for inoperable tumors, or for those areas in which damage to healthy tissue would pose an unacceptable risk. Neutron beam therapy (NBT) is a less widely available form of EBRT that utilizes neutrons. Its clinical use is very limited due to difficulties in the delivery of this treatment modality. Policy/Criteria I. It is the policy of health plans affiliated with Centene Corporation® that proton beam therapy is medically necessary for the following indications: A. Ocular tumors with no distant metastasis. Fiducial markers (tantalum clips) are permitted to allow eye and tumor position verification; or B. Primary or metastatic tumors of the spine where the spinal cord tolerance may be exceeded with conventional treatment or where the spinal cord has previously been irradiated; or C. Tumors that approach or are located at the base of the skull, including but not limited to: chordoma or chondrosarcoma; or D. Primary hepatocellular cancer treated in a hypofractionated regimen; or E. Primary or benign solid tumors in members/enrollees ≤ 18 years old; or F. Genetic syndromes making total volume of radiation minimization crucial such as but not limited to NF-1 patients and retinoblastoma; or G.
    [Show full text]
  • Clinical Progress in Proton Radiotherapy: Biological Unknowns
    cancers Review Clinical Progress in Proton Radiotherapy: Biological Unknowns Laura Vanderwaeren 1,2,3 , Rüveyda Dok 1, Kevin Verstrepen 2,3 and Sandra Nuyts 1,4,* 1 Laboratory of Experimental Radiotherapy, Department of Oncology, KU Leuven, 3000 Leuven, Belgium; [email protected] (L.V.); [email protected] (R.D.) 2 Laboratory of Genetics and Genomics, Centre for Microbial and Plant Genetics, KU Leuven, 3000 Leuven, Belgium; [email protected] 3 Laboratory for Systems Biology, VIB-KU Leuven Center for Microbiology, 3000 Leuven, Belgium 4 Department of Radiation Oncology, Leuven Cancer Institute, University Hospitals Leuven, 3000 Leuven, Belgium * Correspondence: [email protected]; Tel.: +32-1634-7600; Fax: +32-1634-7623 Simple Summary: Proton radiation therapy is a more recent type of radiotherapy that uses proton beams instead of classical photon or X-rays beams. The clinical benefit of proton therapy is that it allows to treat tumors more precisely. As a result, proton radiotherapy induces less toxicity to healthy tissue near the tumor site. Despite the experience in the clinical use of protons, the response of cells to proton radiation, the radiobiology, is less understood. In this review, we describe the current knowledge about proton radiobiology. Abstract: Clinical use of proton radiation has massively increased over the past years. The main reason for this is the beneficial depth-dose distribution of protons that allows to reduce toxicity to normal tissues surrounding the tumor. Despite the experience in the clinical use of protons, the radiobiology after proton irradiation compared to photon irradiation remains to be completely elucidated. Proton radiation may lead to differential damages and activation of biological processes.
    [Show full text]
  • BCBS AL Radiation Therapy Guidelines V3.0.2019
    CLINICAL GUIDELINES Radiation Therapy V3.0.2019 Effective July 15, 2019 Clinical guidelines for medical necessity review of radiation therapy services. © 2019 eviCore healthcare. All rights reserved. Radiation Therapy Criteria V3.0.2019 Please note the following: CPT Copyright 2017 American Medical Association. All rights reserved. CPT is a registered trademark of the American Medical Association. ______________________________________________________________________________________________________ © 2019 eviCore healthcare. All Rights Reserved. Page 2 of 251 400 Buckwalter Place Boulevard, Bluffton, SC 29910 (800) 918-8924 www.eviCore.com Radiation Therapy Criteria V3.0.2019 Please note the following: All information provided by the NCCN is “Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™)©2018/2019 National Comprehensive Cancer Network. The NCCN Guidelines™ and illustrations herein may not be reproduced in any form for any purpose without the express written permission of the NCCN. To view the most recent and complete version of the NCCN Guidelines, go online to NCCN.org.” ______________________________________________________________________________________________________ © 2019 eviCore healthcare. All Rights Reserved. Page 3 of 251 400 Buckwalter Place Boulevard, Bluffton, SC 29910 (800) 918-8924 www.eviCore.com Radiation Therapy Criteria V3.0.2019 Dear Provider, This document provides detailed descriptions of eviCore’s basic criteria (also known as clinical guidelines) for radiation therapy arranged by diagnosis. They have been carefully researched and are continually updated in order to be consistent with the most current evidence-based guidelines and recommendations for the provision of radiation therapy from national medical societies and evidence-based medicine research centers. In addition, the criteria are supplemented by information published in peer-reviewed literature.
    [Show full text]
  • Models for Translational Proton Radiobiology—From Bench to Bedside and Back
    cancers Review Models for Translational Proton Radiobiology—From Bench to Bedside and Back Theresa Suckert 1,2 , Sindi Nexhipi 1,3 , Antje Dietrich 1,2 , Robin Koch 4,5,6 , Leoni A. Kunz-Schughart 1,7 , Emanuel Bahn 4,5,6,8 and Elke Beyreuther 1,9,* 1 OncoRay—National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Helmholtz-Zentrum Dresden-Rossendorf, 01309 Dresden, Germany; [email protected] (T.S.); [email protected] (S.N.); [email protected] (A.D.); [email protected] (L.A.K.-S.) 2 German Cancer Consortium (DKTK), Partner Site Dresden, and German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany 3 Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiooncology-OncoRay, 01309 Dresden, Germany 4 Heidelberg Institute of Radiation Oncology (HIRO), 69120 Heidelberg, Germany; [email protected] (R.K.); [email protected] (E.B.) 5 Department of Radiation Oncology, Heidelberg University Hospital, 69120 Heidelberg, Germany 6 National Center for Tumor Diseases (NCT), 69120 Heidelberg, Germany 7 National Center for Tumor Diseases (NCT), Partner Site Dresden, 01307 Dresden, Germany 8 German Cancer Research Center (DKFZ), Clinical Cooperation Unit Radiation Oncology, 69120 Heidelberg, Germany 9 Helmholtz-Zentrum Dresden—Rossendorf, Institute of Radiation Physics, 01328 Dresden, Germany * Correspondence: [email protected] Citation: Suckert, T.; Nexhipi, S.; Dietrich, A.; Koch, R.; Simple Summary: An increasing number of cancer patients are treated with proton therapy. Never- Kunz-Schughart, L.A.; Bahn, E.; theless, there are still open questions that require preclinical studies, for example, those regarding Beyreuther, E.
    [Show full text]
  • Proton Beam Radiation Therapy – Commercial Medical Policy
    UnitedHealthcare® Commercial Medical Policy Proton Beam Radiation Therapy Policy Number: 2021T0132CC Effective Date: May 1, 2021 Instructions for Use Table of Contents Page Related Commercial Policy Coverage Rationale ........................................................................... 1 • Intensity-Modulated Radiation Therapy Documentation Requirements......................................................... 2 • Radiation Therapy: Fractionation, Image-Guidance, Definitions ........................................................................................... 2 and Special Services Applicable Codes .............................................................................. 2 • Stereotactic Body Radiation Therapy and Description of Services ..................................................................... 4 Stereotactic Radiosurgery Clinical Evidence ............................................................................... 4 U.S. Food and Drug Administration ..............................................18 Community Plan Policy References .......................................................................................18 • Proton Beam Radiation Therapy Policy History/Revision Information..............................................23 Medicare Advantage Coverage Summary Instructions for Use .........................................................................23 • Radiologic Therapeutic Procedures Coverage Rationale Note: This policy applies to persons 19 years of age and older. Proton beam radiation
    [Show full text]
  • 2020 Annual Report
    Advanced Oncotherapy plc Annual Report 2020 Democratising Proton Therapy Advancing cancer treatment with innovative, cost effective technology Advanced Oncotherapy plc. Annual Report 2017 Advanced Oncotherapy plc Annual Report 2018 Advancing cancer treatment with innovative, cost effective technology Advancing cancer treatment with innovative, cost effective technology Advanced Oncotherapy plc Advanced Oncotherapy plc Annual Report Annual Report 2019 2020 Democratising Proton Therapy Advancing cancer treatment with innovative, cost effective technology Democratising Proton Therapy Advancing cancer treatment with innovative, cost effective technology This report is available on our website www.avoplc.com/en-gb/Investors/Company-Documents ADVANCED ONCOTHERAPY PLC 1 TO OUR SHAREHOLDERS STRATEGIC REPORT OUR PURPOSE We are driven by our purpose: democratising proton therapy. Just as the mobile revolution democratised communication among people, healthcare must be democratised. At Advanced Oncotherapy, we believe access to healthcare is a fundamental human right. Yet, the provision of healthcare is still not universal and many people cannot afford quality health services. Proton therapy is one of the many segments in healthcare where a different global approach that is truly democratic must emerge. Fundamentally, we believe in a new model that will change the way we treat cancer, and the relationship between patients and physicians as we know it. TO OUR SHAREHOLDERS FINANCIAL REPORT Consolidated Statement of Profit or Loss and STRATEGIC REPORT
    [Show full text]
  • Best Practices in Identifying Proton-Appropriate Patients Presented by Dr
    Best Practices in Identifying Proton-Appropriate Patients Presented by Dr. Ramesh Rengan Professor, Department of Radiation Oncology, University of Washington School of Medicine Medical Director, SCCA Proton Therapy Center Radiation Oncologist, University of Washington Medical Center Introduction Protons are a form of radiation treatment that, for a subset of patients, may provide a clinical benefit when compared with standard radiotherapy. 2 Finding the 3% Your challenge: Proton therapy is appropriate in only How can I make sure that 3-10% of solid tumor cases. my patient is But for that group, getting the best there are many expected treatment plan? clinical benefits. 3 Clinical Benefits of Proton Therapy • Ability to apply higher therapeutic dosages, because the beam delivers the most radiation at the tumor site, reducing overall exposure • Expected reduction in radiation-caused secondary cancers - Particularly critical to young people and pediatric cases - Important to anyone with long life expectancy • Less radiation damage to nearby healthy tissue - Particularly important in ocular, brain, lung and breast cancers • Clinical evidence to support fewer side effects compared to X-rays in certain patients So Why Only 3-10%? • 30% of solid tumor cancer patients receive radiation (of any type) Cases suitable for proton therapy • Protons are not generally applicable for metastasized cancers – Half of the 60% are treated for palliative, versus curative, care Of 100% of cancer cases … • Limited resource 60% of these are solid tumor cases 30% of these are suitable for radiation • Cost 3-10% of these are suitable for protons • Complexity of treatment planning and delivery • Availability of proton centers 5 When Is Proton Therapy Appropriate? Will share infographic section once final.
    [Show full text]